Computational drug designer Schrödinger has entered into a five-year early drug discovery collaboration with Sanofi in which Schrödinger will provide target analysis and validation to lead identification and lead optimization for as many as ten drug discovery...
The strategic partnership comes with Sanofi providing €250m to Evotec, including €40m upfront, as part of efforts to discover new drug candidates, including in the area of oncology, and specifically at Sanofi’s R&D site in Toulouse, France.
Fluctuations in regulations over the past few years have reduced the number of clinical trials run on the subcontinent, but now governing bodies are looking at new ways to attract trials and further control the industry.
Charles River Laboratories is nearing the acquisition of an early-stage drug discovery company, CEO James Foster told attendees at the Leerink Swann Global Healthcare Conference last week.
Evotec and Sanofi have entered into exclusive negotiations for a major strategic partnership that will include a €250m ($310m) minimum guaranteed commitment from Sanofi over the next five years.
MPI Research announced Monday it has acquired the assets of Kalamazoo, Michigan-based CRO Jasper Clinical Research & Development, which provides early-stage human clinical testing of new drugs for an undisclosed amount.
Evotec has announced positive milestone news this week, revealing that efforts to develop an endometriosis drug with Bayer have moved into preclinical testing.
A few months after announcing its arrival in South Korea, Celerion and the Korean Drug Development Fund (KDDF) have agreed to collaborate to provide drug development expertise and support for the emerging industry.
Biofocus says it is literally bringing its scientists closer together to aid its drug discovery services with a new 60,000 square foot facility in Cambridge, UK.
Cutbacks are prompting more sponsors to outsource library design and screening during drug discovery according to UK-based software and consulting firm Cresset.
Over the next three years Pfizer will work with the Sanford Burnham Medical Research Institute to discover therapeutic targets to prevent and treat complications related to obesity and diabetes.
Evotec says it is confident underlying growth, expansion of its clinical stage pipeline and upcoming milestone payments will counter Q1’s downcast results.
Outsourcing-Pharma.com presents the low down on new services forged by partnerships and M&A (mergers and acquisitions), including a molecular biology offering for Quotient, Onyx’s added purification and separation capabilities, and Accenture’s new...
Outsourcing-Pharma presents its weekly round-up of the latest chops and changes within the pharmaceutical jobs market, with news from Patheon, AmerisourceBergen and Premier Research.
VivoPharm says its new agreement with primary patient-derived tumour creators EPO-GmbH will bring drug candidate selection to a “new level” for US drug researchers.
Sigma-Aldrich says it is a step closer to becoming a one-stop-shop for biopharmas in the drug discovery process after it inked a takeover agreement with biological testing firm BioReliance.
The Hamner Institutes for Health Sciences and private equity firm PBM Capital Group (PBM) have thrashed out a venture for toxicity testing which they say could save the drug discovery industry billions.
A new study claims that almost 60 per cent of clinical trial protocols for new drugs are amended during the trial, but one-third of those changes could have been avoided.
Eli Lilly has unveiled plans to close its Singapore R&D centre by the end of the year and relocate discovery operations to its global headquarters in the US.
Southern Research Institute is acquiring BioCryst Pharmaceuticals’ bioanalytical laboratory assets and personnel in a move towards expanding its bioanalytical service offerings.
Galapagos’ acquisition, Argenta, has signed up to a $46m cancer drug discovery service deal with Janssen Pharmaceutica, aimed at delivering novel cancer drug candidates.
InhibOx and the Cambridge Crystallographic Data Centre (CCDC) say new drug discovery services partnership is motivated by market need for CADD expertise.
Outsourcing to Asia is changing “from a tactical to a strategic imperative” as a result of the region gaining the capabilities needed to perform work high up the biopharma value chain, according to Quintiles.
TTP LabTech has launched a contract screening service to assist various aspects of clients’ drug development programmes, from target identification through to preclinical toxicology.
MDS Pharma Services is renovating and expanding its Taiwanese discovery pharmacology operation in response to growing global demand for work performed in Asia.
BioFocus DPI, the service division of Belgian drug discovery firm Galapagos, made a profit of €3.4m on revenues a little over €56m in 2008, reversing a loss of about the same magnitude in 2007.
Indian contract research firm Jubilant Biosys has teamed up with US company BioLeap to offer drug early-stage discovery services which incorporate computational drug design.
WuXi AppTec is to use ThalesNano’s H-Cube for laboratory-based hydrogenation, which the CRO believes offers advantages in drug discovery over traditional batch processes.
Drug discovery informatics and services provider Tripos International has continued to flourish under the ownership of Vector Capital and is collaborating with AstraZeneca (AZ) to improve drug discovery workflows.
BioReliance has had to significantly expand its Rockville, US, facility and hire new staff in order to accommodate the growing demand for its genetic toxicology (GeneTox) testing services.
MDS Analytical Technologies has followed its acquisition of
Molecular Devices last year by snapping up high content screening
(HCS) experts Blueshift for $15m (€9.45m).
BioFocus DPI, a subsidiary of Galapagos, has launched a new
platform for drug discovery at the Society for Biomolecular
Sciences Annual Conference taking place this week in St Louis.
Novo Nordisk and Merck & Co have both indicated they have their
eye on expanding their drug discovery and manufacturing presence in
India and forging new research partnerships among companies in the
country.
Artel has introduced a new feature for its Multichannel
Verification System (MVS), which includes an automation function
that allows for time savings and reducing human error.
Tripos Discovery Research (TDR) has risen from the ashes
surrounding the liquidation of its previous owners Tripos, Inc. to
land a 'library enrichment' deal with Schering-Plough.
China's second largest contract research organisation (CRO)
ShangPharma has attracted $30m (€21m) from US private
investment firm TPG as the Asian pharma market continues to simmer.
Agilent and BioTrove are collaborating to deliver ultra
high-throughput sample preparation and mass spectrometry (MS)
systems to speed the analysis of in vitro assays used in
drug development.
Pfizer has launched a new independent biotech centre and announced
five new senior appointments - not least a new head of R&D
- all geared towards reinvigorating the firm.
Researchers from Novartis have published results using
high-throughput screening (HTS) mass spectrometry (MS) techniques
for the identification of enzyme inhibitors.
Thermo Fisher Scientific has opened a new RNAi Discovery and
Therapeutics Services Laboratory to help pharmaceutical companies
in their quest for new drugs.
